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A 49-year-old Hispanic male with stage IV non-squamous, non–small-cell lung cancer (NSCLC) on maintenance 
bevacizumab treatment, presented with progressive paresthe-
sias over the back, abdomen, and chest; left foot numbness; 
unsteady gait; and mid-back pain. He had been diagnosed 
with advanced lung cancer 14 months prior, including bulky 
thoracic adenopathy, brain metastases, and malignant pleural 
and pericardial effusions. Imaging demonstrated no spinal, 
dural, or vertebral lesions. He was initially treated with peri-
cardiectomy and whole brain radiation therapy (RT), followed 
by administration of six cycles carboplatin-paclitaxel plus 
bevacizumab then 12 cycles of bevacizumab maintenance 
monotherapy. To evaluate the patient’s neurologic symptoms, 
magnetic resonance imaging (MRI) of the spine was per-
formed, which suggested the presence of intramedullary spi-
nal cord metastases (ISCM) at the T4 level, with associated 
hemorrhage (Fig. 1A, B). Additional imaging revealed stable 
disease elsewhere. He was started on systemic steroids, and 
bevacizumab was discontinued. Neurosurgery was consulted 
with recommendation against surgical intervention. RT (45 
Gray/25 fractions) was delivered to the intramedullary metas-
tases. Back pain resolved, neurologic symptoms improved, 
and steroids were discontinued. MRI evaluation after RT dem-
onstrated reduction in size of the metastases with resolution of 
hemorrhage. (Fig. 1C, D).
Discussion
This could be the first reported case of bevacizumab-
associated intramedullary hemorrhage in NSCLC. ISCM is a 
rare event, reported to affect only 0.1–0.4% of cancer patients 
and typically associated with poor prognosis.1 Of these cases, 
approximately 55% are attributed to lung cancer.1 Clinical 
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FiGuRE 1.  Sagittal view of A) T1 post contrast magnetic 
resonance imaging (MRI) of thoracic spine and B) T1 non-
contrasted MRI at the time of initial presentation. A discrete 
enhancing lesion is noted at the level of fourth thoracic spine 
concerning for intramedullary spinal cord metastases (dashed 
circle) and extensive heterogeneous signal (bold arrows) 
concerning for blood products/hemorrhage surrounding the 
lesion are noted. Sagittal view of C) T1 post contrast MRI and 
D) T1 non-contrasted MRI, of thoracic spine approximately 2 
months after completion of radiation therapy at similar plane 
to figure 1A image. This demonstrates reduction in size of 
the intramedullary metastases (dashed circle) and significant 
reduction in hemorrhage and mass effect from the tumor. No 
other new lesions were detected.
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experience with bevacizumab in the presence of central nervous 
system (CNS) lesions can be extrapolated from that described 
with brain metastases. The rate of cerebral hemorrhage in 
NSCLC patients on bevacizumab is an equally rare event, rang-
ing from 0.8% to 3.3%.2 Given the rarity of both ISCM and CNS 
hemorrhage associated with bevacizumab treatment, ISCM 
hemorrhage from bevacizumab should be an extremely rare 
event. In this case, with excellent prolonged control of his intra-
cranial and extracranial disease, we surmise that this metastatic 
disease occurred or persisted at a site where chemotherapy gen-
erally has poorer penetrance. Although there are concerns that 
bevacizumab can be associated with CNS hemorrhage,3 clini-
cal data suggest bevacizumab should be considered safe to use 
in patients with pretreated brain metastases.4 Consistent with 
these reports, our patient, who had his brain metastases irradi-
ated, never developed intracranial bleeding. Although intracra-
nial experiences in NSCLC suggest that bevacizumab is safe to 
use in treated CNS metastatic lesions, specifically for ISCM, 
there is not enough experiences to be certain of this. There is 
one report of a glioblastoma patient with intramedullary dis-
ease, treated with RT followed by bevacizumab, without report 
of bleeding events.5 However, this experience is limited in that 
the patient only survived 3 months. In our patient, bevacizumab 
was not resumed for safety concerns.
In summary, we present a patient with metastatic NSCLC 
who developed hemorrhage of ISCM while on bevacizumab. 
Although rare, ISCM hemorrhage should be considered, par-
ticularly in long-term survivors with metastatic NSCLC on 
bevacizumab presenting with concerning symptoms. Early 
recognition and prompt initiation of appropriate intervention 
may help reduce risk of lasting neurologic deficits.
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